Defense Department Approves Ketamine-Based Antidepressant for Some Patients | WHAT REALLY HAPPENED

Defense Department Approves Ketamine-Based Antidepressant for Some Patients

Spravato, the controversial ketamine-based nasal spray used to treat severe depression, will be available to Tricare beneficiaries on a case-by-case basis beginning May 18, Defense Health Agency officials announced Friday.

The medication, a synthetic version of the anesthetic ketamine, will be available to patients with treatment-resistant depression who receive prior authorization from Tricare.

The move comes a little over a year after the U.S. Food and Drug Administration fast-tracked approval of the drug, which has a similar makeup as the hallucinogenic club drug known as Special K.

Comments

SHARE THIS ARTICLE WITH YOUR SOCIAL MEDIA